Drugs / irofulven
irofulven
also known as
MGI-114 · 6-Hydroxymethylacylfulvene · HMAF · (hydroxymethyl)acylfulvene · Irofulvene · Irofulveno · LP-100 · NSC-683863
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003997 | Jul 1999 → Oct 2000 | leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003370 | Aug 1998 → Mar 2006 | childhood malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00374660 | Jun 2003 → Apr 2007 | liver cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00012038 | Jul 2001 → Oct 2003 | central nervous system neoplasm | New Approaches to Brain Tumor Therapy Consortium | Completed | No outcome recorded |
| Phase 215 trials · 1 missed | ||||||
| Phase 2 | NCT03643107 | Oct 2018 → Oct 2021 | castration-resistant prostate carcinoma | Allarity Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00124527 | Mar 2005 → Aug 2006 | thyroid cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00124566 | Jun 2004 → Jan 2006 | prostate cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00062257 | Jun 2003 → Sep 2006 | gastric cancer | Cancer Therapeutics Research Group | Completed | No outcome recorded |
| Phase 2 | NCT00053365 | Jun 2003 → Jul 2010 | malignant epithelial tumor of ovary, peritoneum cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005031 | Aug 2000 → Oct 2004 | endometrial cancer | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00005070 | Jan 2000 → May 2001 | cervical cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00005968 | Nov 1999 → Dec 2002 | cutaneous melanoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00003796 | May 1999 → Dec 2003 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003786 | Apr 1999 → Nov 2000 | colorectal cancer | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003760 | Nov 1998 → May 2000 | malignant pancreatic neoplasm | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT00003666 | Nov 1998 → Sep 2004 | lung cancer | Alliance for Clinical Trials in Oncology | Completed | Missed primary |
| Phase 2 | NCT00019552 | Sep 1998 → Apr 2004 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003441 | Aug 1998 → Nov 2000 | colorectal cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00003390 | Jun 1998 → Aug 2004 | kidney cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00033735 | Jan 2000 → Jun 2003 | malignant pancreatic neoplasm | Eisai Inc. | Completed | No outcome recorded |
Press releases naming this drug 11 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | irofulven | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005031 ↗ |
| Known as | (hydroxymethyl)acylfulvene | ChEMBL registry synonym — accepted as the source's own label CHEMBL118218 ↗ |
| Known as | 6-Hydroxymethylacylfulvene | “Determine the objective response rate of patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum treated with 6-hydroxymethylacylfulvene (MGI-114).” NCT00003786 ↗2“A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma” NCT00005070 ↗ |
| Known as | HMAF | “PURPOSE: To assess the efficacy and toxicity of 6-hydroxymethylacylfulvene (HMAF; MGI-114, irofulven) as therapy for relapsed or refractory non-small cell lung cancer.” PMID 15301880 ↗ Sep 20041“A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma” NCT00005070 ↗ |
| Known as | Irofulvene | ChEMBL registry synonym — accepted as the source's own label CHEMBL118218 ↗ |
| Known as | Irofulveno | ChEMBL registry synonym — accepted as the source's own label CHEMBL118218 ↗ |
| Known as | LP-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL118218 ↗ |
| Known as | MGI-114 | “Determine the objective response rate of patients with metastatic or locally recurrent adenocarcinoma of the colon or rectum treated with 6-hydroxymethylacylfulvene (MGI-114).” NCT00003786 ↗4“PURPOSE: To assess the efficacy and toxicity of 6-hydroxymethylacylfulvene (HMAF; MGI-114, irofulven) as therapy for relapsed or refractory non-small cell lung cancer.” PMID 15301880 ↗ Sep 2004 “Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.” PMID 15122083 ↗ Aug 2004 “A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma” NCT00005070 ↗ “Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.” PMID 16317728 ↗ Aug 2006 |
| Known as | NSC-683863 | ChEMBL registry synonym — accepted as the source's own label CHEMBL118218 ↗ |
| Modality | Small molecule | — CHEMBL118218 ↗ |
| Route | Intravenous | “IV over 5 minutes daily for 5 consecutive days” NCT00003441 ↗ |